{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:30:34Z","timestamp":1786379434220,"version":"build-2736575974"},"reference-count":25,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver Cancer"],"abstract":"<jats:p>Introduction: Beta-blockers reduce portal hypertension; however, evidence comparing carvedilol and propranolol in patients with hepatocellular carcinoma (HCC) is lacking. We aimed to compare the clinical outcomes of carvedilol versus propranolol in patients with HCC. Methods: Using the Korean National Health Insurance Service database (2009\u20132023), we identified 11,124 patients with newly diagnosed HCC who were prescribed either carvedilol (n = 2,457) or propranolol (n = 8,667) within 180 days of diagnosis. The primary outcome was all-cause mortality, and the secondary outcome was hepatic decompensation. Multivariable Cox regression and 1:2 PS matching were used as primary analytical approaches, with sensitivity analyses restricted to 6-month survivors and a new-user design. Results: During a median follow-up of 1.5 years, carvedilol use was associated with a significantly lower risk of hepatic decompensation (adjusted hazard ratio [aHR] 0.67; 95% confidence interval [CI] 0.62\u20130.72) and all-cause mortality (aHR 0.84; 95% CI 0.79\u20130.90) compared to propranolol. In the 1:2 PS-matched cohort (n = 5,922), these associations remained consistent for both decompensation (HR 0.68; 95% CI 0.63\u20130.74) and mortality (HR 0.84; 95% CI 0.78\u20130.90). These benefits were consistent across various subgroups, and in sensitivity analysis excluding early death within 6 months from diagnosis and using a new-user design. Conclusion: In patients with HCC, carvedilol was associated with better survival and lower risk of hepatic decompensation than propranolol. Carvedilol may be the preferred beta-blocker over propranolol in the setting of HCC.<\/jats:p>","DOI":"10.1159\/000553325","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:01:16Z","timestamp":1782748876000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study"],"prefix":"10.1159","author":[{"given":"Byeong Geun","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeongcheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-3450","authenticated-orcid":false,"given":"Geum-Youn","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-7714","authenticated-orcid":false,"given":"Danbee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14977"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.019"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2025.01.097"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31875-0"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.12.001"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000647"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.02.005"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9765-y"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.017"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.07.020"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001026"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7110"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv319"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.23838\/pfm.2021.00135"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016640"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4255-6"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102496"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101681"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15559"}],"container-title":["Liver Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000553325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:00:47Z","timestamp":1786377647000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000553325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1159\/000553325","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32824865","asserted-by":"subject"}]},"ISSN":["2235-1795","1664-5553"],"issn-type":[{"value":"2235-1795","type":"print"},{"value":"1664-5553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}